atomoxetine hydrochloride has been researched along with guanfacine in 61 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (18.03) | 29.6817 |
| 2010's | 33 (54.10) | 24.3611 |
| 2020's | 17 (27.87) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Biederman, J; Spencer, T; Wilens, T | 1 |
| Acosta, MT; Castellanos, FX | 1 |
| Friedman, JI; Gorman, JM; Stewart, DG | 1 |
| Reeves, G; Schweitzer, J | 1 |
| Henderson, TA | 1 |
| Banaschewski, T; Heise, CA; Himpel, S; Rothenberger, A | 1 |
| Arnsten, AF; Biederman, J; Culpepper, L; Doyle, AE; Faraone, SV; Safren, SA; Spencer, TJ; Weiss, MD; Wilens, TE | 1 |
| Wilens, TE | 1 |
| Bukstein, OG; Crismon, ML; Manos, MJ; Tom-Revzon, C | 1 |
| Levy, F | 1 |
| Bari, A; Eagle, DM; Mar, AC; Robbins, TW; Robinson, ES | 1 |
| Roman, MW | 1 |
| Chae, S; Patel, A; Steinberg-Epstein, R; Wigal, SB | 1 |
| Kaplan, G; Newcorn, JH | 1 |
| Arnsten, AF; Pliszka, SR | 1 |
| Arnsten, AF | 1 |
| Bidwell, LC; Kollins, SH; McClernon, FJ | 1 |
| Franke, AG; Huss, M; Konrad, A; Lieb, K | 1 |
| Huang, YS; Tsai, MH | 1 |
| Aspinall, AT; Caprioli, D; Dalley, JW; Economidou, D; Fernando, AB; Hipólito, L; Moreno, M; Newman, AH; Robbins, TW; Spoelder, M; Theobald, DE; Zou, MF | 1 |
| Chung, K; Duong, S; Wigal, SB | 1 |
| Erder, MH; Hodgkins, PS; Lu, M; Signorovitch, J; Sikirica, V; Wu, EQ; Xie, J | 1 |
| Beauchemin, C; Hodgkins, PS; Lachaine, J; Sasane, R | 1 |
| Chen, KS; Erder, MH; Hodgkins, P; Lu, M; Signorovitch, JE; Sikirica, V; Wu, EQ; Xie, J | 1 |
| Banaschewski, T; Buitelaar, J; Coghill, D; Cortese, S; Danckaerts, M; Dittmann, RW; Graham, J; Holtmann, M; Sergeant, J; Taylor, E | 1 |
| Alexander, GC; Conti, RM; Dorsey, ER; Dusetzina, SB; Garfield, CF; Higashi, AS; Huskamp, HA; Kornfield, R; Watson, S | 1 |
| Connor, DF; Faraone, SV; Jensen, PS; Miesle, LM; Rostain, A | 1 |
| Calleja-Pérez, B; Fernández-Jaén, A; Fernández-Perrone, AL; López-Arribas, S; Martín Fernández-Mayoralas, D; Muñoz-Jareño, N | 1 |
| Dammerman, R; Erder, MH; Findling, RL; Hodgkins, P; Lu, M; Signorovitch, J; Sikirica, V; Wu, EQ; Xie, J | 1 |
| Bloomfield, R; Hervas, A; Huss, M; Johnson, M; Lyne, A; McNicholas, F; Robertson, B; Sikirica, V; Sreckovic, S; van Stralen, J | 1 |
| Chen, W; Huss, M; Ludolph, AG | 1 |
| Blumenschein, K; Moga, DC; Sohn, M; Talbert, J | 1 |
| Chan, E; Fogler, JM; Hammerness, PG | 1 |
| Chandra, A; Erder, MH; Shafrin, J; Shrestha, A; Sikirica, V | 1 |
| Jain, R; Katic, A | 1 |
| Anderson, RH; Mattingly, GW | 1 |
| Naguy, A | 1 |
| Charman, T; Findon, JL; Howes, OD; King, BH; Loth, E; McAlonan, GM; McCracken, JT; Murphy, DG; Parr, JR; Povey, C; Rogdaki, M; Santosh, P; Simonoff, E; Wallace, S; Wichers, RH | 1 |
| Alatorre, CI; Faries, DE; Gelwicks, S; Haynes, VS; Kelsey, DK; Molife, C; Nyhuis, A | 1 |
| Hasegawa, M; Horiguchi, N; Jino, K; Kano, T; Kobayashi, M; Nishitomi, K; Shinohara, S; Yano, K | 1 |
| Osland, ST; Pringsheim, T; Steeves, TD | 1 |
| Bastiaens, L; Galus, J; Scott, O | 1 |
| Chawla, P; Redding, ZV; Sabol, KE | 1 |
| Grimmsmann, T; Himmel, W | 1 |
| Ameis, SH; Anagnostou, E; Anderson, KK; Beswick, A; Gorman, DA; Lai, MC; Rodrigues, R; Szatmari, P | 1 |
| Cortese, S | 1 |
| Choudhury, ME; Eguchi, M; Fukuda, M; Ishii, E; Jogamoto, T; Kihara, N; Kubo, M; Miyanishi, K; Nagai, M; Nomoto, M; Sato, A; Shimizu, YI; Tanaka, J; Utsunomiya, R; Yano, H | 1 |
| Bai, Z; Charach, A; Chojecki, D; Eagles, C; Elliott, J; Hossain, A; Hsieh, SC; Husereau, D; Johnston, A; Kelly, SE; Mamdani, M; Skidmore, B; Tsakonas, E; Wells, GA | 1 |
| Cutler, AJ; Jain, R; Mattingly, GW; O'Neal, W | 1 |
| Biederman, J; Firmin, ES; Hoskova, B; Joshi, G; Wilens, T | 1 |
| Bloch, MH; Farhat, LC | 1 |
| Chernoff, CS; Hynes, TJ; Winstanley, CA | 1 |
| Hakosima, Y; Harada, I; Inazaki, K; Itagaki, K; Kurokouchi, T; Mizumoto, Y; Namekata, S; Okada, T; Saito, K; Sasaki, S; Sasaki, Y; Shinohara, R; Sugimoto, K; Sunakawa, H; Takahashi, M; Tanase, S; Toguchi, Y; Tsujii, N; Usami, M; Yoshida, Y; Yoshimura, Y | 1 |
| Banaschewski, T; Bölte, S; Buitelaar, JK; Coghill, D; Cortese, S; Häge, A; Hohmann, S; Jonsson, U; Nobel Norrman, H; Pan, PY; Şahpazoğlu Çakmak, SS | 1 |
| Holden, JM | 1 |
| Dittmann, RW; Krone, B; Newcorn, JH | 1 |
| Böker, KO; Di Fazio, P; Jäckle, K; Lehmann, W; Schilling, AF; Wagener, N; Weiser, L | 1 |
| Beltran-Navarro, B; Galvez-Contreras, AY; Gonzalez-Castaneda, RE; Gonzalez-Perez, O; Vargas-de la Cruz, I | 1 |
| Bellato, A; Cortese, S; Faraone, SV; Khoury, NM; Radonjić, NV | 1 |
| Anicama, A; Cárdenas, A; Velarde, M | 1 |
34 review(s) available for atomoxetine hydrochloride and guanfacine
| Article | Year |
|---|---|
Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Child; Clonidine; Delayed-Action Preparations; Evidence-Based Medicine; Guanfacine; Humans; Methylphenidate; Propylamines | 2004 |
Potential noradrenergic targets for cognitive enhancement in schizophrenia.
Topics: Adrenergic alpha-Agonists; Atomoxetine Hydrochloride; Cognition Disorders; Guanfacine; Humans; Norepinephrine; Prefrontal Cortex; Propylamines; Schizophrenia | 2004 |
Pharmacological management of attention-deficit hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Amphetamines; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Child; Clonidine; Guanfacine; Humans; Methylphenidate; Propylamines | 2004 |
The safety of non-stimulant agents for the treatment of attention-deficit hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Adult; Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Child; Clonidine; Desipramine; Guanfacine; Humans; Imipramine; Nortriptyline; Propylamines | 2005 |
Mechanism of action of agents used in attention-deficit/hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Child; Clonidine; Guanfacine; Humans; Nicotinic Antagonists; Pharmacogenetics; Propylamines | 2006 |
Changes and challenges: managing ADHD in a fast-paced world.
Topics: Algorithms; Antihypertensive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulants; Child; Comorbidity; Drug Delivery Systems; Family; Guanfacine; Humans; Modafinil; Patient Compliance; Prodrugs; Propylamines; Quality of Life; Randomized Controlled Trials as Topic; Substance-Related Disorders; Treatment Outcome | 2007 |
Dopamine vs noradrenaline: inverted-U effects and ADHD theories.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Alleles; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Catechol O-Methyltransferase; Dopamine; Guanfacine; Humans; Memory, Short-Term; Nerve Net; Norepinephrine; Polymorphism, Genetic; Prefrontal Cortex; Propylamines; Receptors, Adrenergic, alpha-2; Receptors, Dopamine D4; Space Perception; Thalamus | 2009 |
Advances in the treatment of attention-deficit/hyperactivity disorder: a guide for pediatric neurologists.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Dextroamphetamine; Guanfacine; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Propylamines | 2010 |
Pharmacotherapy for child and adolescent attention-deficit hyperactivity disorder.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Guanfacine; Humans; Methylphenidate; Propylamines | 2011 |
Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Catecholamines; Central Nervous System Stimulants; Dopamine; Guanfacine; Humans; Models, Neurological; Norepinephrine; Prefrontal Cortex; Propylamines; Receptors, Catecholamine | 2011 |
Catecholamine influences on dorsolateral prefrontal cortical networks.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Animals; Arousal; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Catecholamines; Cognition; Guanfacine; Humans; Memory, Short-Term; Methylphenidate; Models, Neurological; Neural Pathways; Prefrontal Cortex; Propylamines; Synaptic Transmission | 2011 |
Cognitive enhancers for the treatment of ADHD.
Topics: Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cholinergic Agents; Clonidine; Cognition; Executive Function; Guanfacine; Humans; Intelligence; Methylphenidate; Nootropic Agents; Propylamines; Reward; Social Behavior | 2011 |
[Stimulant and non-stimulant medication in current and future therapy for ADHD].
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulants; Child; Dextroamphetamine; Fatty Acids, Omega-3; Guanfacine; Histamine Agonists; Humans; Isoxazoles; Lisdexamfetamine Dimesylate; Memantine; Methylphenidate; Modafinil; Off-Label Use; Propylamines; Pyridines; Pyrrolidines; Receptors, AMPA | 2012 |
Long-term outcomes with medications for attention-deficit hyperactivity disorder: current status of knowledge.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clonidine; Delayed-Action Preparations; Guanfacine; Humans; Propylamines; Treatment Outcome | 2011 |
Metabolic, toxicological, and safety considerations for drugs used to treat ADHD.
Topics: Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clinical Trials as Topic; Clonidine; Comorbidity; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Guanfacine; Humans; Methylphenidate; Propylamines | 2012 |
Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Size; Cardiovascular Diseases; Central Nervous System Stimulants; Child; Clonidine; Dextroamphetamine; Growth Disorders; Guanfacine; Heart Rate; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Propylamines; Psychoses, Substance-Induced; Seizures; Sleep Wake Disorders; Substance-Related Disorders; Suicide Prevention; Tic Disorders; Treatment Outcome | 2013 |
Toward quality care in ADHD: defining the goals of treatment.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Dextroamphetamine; Goals; Guanfacine; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Propylamines; Quality of Health Care; Treatment Outcome | 2015 |
[Autism and attention deficit hyperactivity disorder: pharmacological intervention].
Topics: Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Brain; Central Nervous System Stimulants; Child; Child Development Disorders, Pervasive; Clonidine; Dopamine Uptake Inhibitors; Drug Evaluation; Guanfacine; Humans; Methylphenidate; Neuroimaging; Propylamines; Psychotropic Drugs; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Europe; Guanfacine; Humans; Treatment Outcome | 2016 |
Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clonidine; Delayed-Action Preparations; Guanfacine; Humans; Methylphenidate; Motivation; Psychotherapy; Randomized Controlled Trials as Topic; Social Skills | 2016 |
Current and Investigational Medication Delivery Systems for Treating Attention-Deficit/Hyperactivity Disorder.
Topics: Adrenergic Agents; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clinical Trials as Topic; Clonidine; Guanfacine; Humans; Methylphenidate; Treatment Outcome | 2016 |
Optimizing outcomes in ADHD treatment: from clinical targets to novel delivery systems.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Anxiety Disorders; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Central Nervous System Stimulants; Clonidine; Comorbidity; Delayed-Action Preparations; Depressive Disorder; Dextroamphetamine; Guanfacine; Humans; Methylphenidate | 2016 |
Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Brain; Consensus; Guanfacine; Humans; Melatonin; Methylphenidate; Psychopharmacology; Sleep Wake Disorders | 2018 |
Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Clonidine; Desipramine; Dextroamphetamine; Female; Guanfacine; Humans; Male; Methylphenidate; Randomized Controlled Trials as Topic; Selegiline; Tic Disorders | 2018 |
Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Central Nervous System Stimulants; Child; Guanfacine; Humans; Methylphenidate | 2021 |
Pharmacologic Treatment of Attention Deficit-Hyperactivity Disorder.
Topics: Adolescent; Adult; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Child, Preschool; Growth; Guanfacine; Heart Rate; Humans; Hypertension; Methylphenidate; Patient Dropouts; Polymers; Practice Guidelines as Topic; Treatment Outcome | 2020 |
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Topics: Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bayes Theorem; Bupropion; Central Nervous System Stimulants; Dextroamphetamine; Drug-Related Side Effects and Adverse Reactions; Female; Guanfacine; Humans; Lisdexamfetamine Dimesylate; Male; Methylphenidate; Modafinil; Network Meta-Analysis; Quality of Life; Randomized Controlled Trials as Topic | 2020 |
Current and future nonstimulants in the treatment of pediatric ADHD: monoamine reuptake inhibitors, receptor modulators, and multimodal agents.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clonidine; Guanfacine; Humans; United States | 2022 |
Pharmacotherapy of attention deficit/hyperactivity disorder in individuals with autism spectrum disorder: A systematic review of the literature.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; Guanfacine; Humans; Intellectual Disability; Methylphenidate; Treatment Outcome | 2021 |
Headache in ADHD as comorbidity and a side effect of medications: a systematic review and meta-analysis.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Guanfacine; Headache; Humans; Methylphenidate; Randomized Controlled Trials as Topic | 2022 |
Nonstimulant Treatments for ADHD.
Topics: Adrenergic alpha-2 Receptor Agonists; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clonidine; Guanfacine; Humans | 2022 |
Therapeutic Approaches for ADHD by Developmental Stage and Clinical Presentation.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Guanfacine; Humans; Methylphenidate | 2022 |
Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Guanfacine; Humans; Randomized Controlled Trials as Topic; Viloxazine | 2023 |
[Attention deficit hyperactivity: pharmacotherapy through life].
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Child; Diagnostic and Statistical Manual of Mental Disorders; Educational Status; Guanfacine; Humans; Quality of Life | 2023 |
2 trial(s) available for atomoxetine hydrochloride and guanfacine
| Article | Year |
|---|---|
Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cost-Benefit Analysis; Delayed-Action Preparations; Female; Guanfacine; Humans; Male; Markov Chains; Propylamines; Quality-Adjusted Life Years; Treatment Outcome | 2012 |
Efficacy and safety of extended-release guanfacine hydrochloride in children and adolescents with attention-deficit/hyperactivity disorder: a randomized, controlled, phase III trial.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Female; Guanfacine; Humans; Male; Propylamines; Psychiatric Status Rating Scales | 2014 |
25 other study(ies) available for atomoxetine hydrochloride and guanfacine
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
[Tourette syndrome: an analysis of its comorbidity and specific treatment].
Topics: Adrenergic alpha-Agonists; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Comorbidity; Guanfacine; Humans; Obsessive-Compulsive Disorder; Propylamines; Tourette Syndrome | 2004 |
Mania induction associated with atomoxetine.
Topics: Aggression; Anger; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bipolar Disorder; Child; Drug Therapy, Combination; Guanfacine; Humans; Irritable Mood; Male; Propylamines; Sympathomimetics; Violence | 2004 |
New developments in the treatment of ADHD.
Topics: Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clonidine; Cognitive Behavioral Therapy; Guanfacine; Humans; Modafinil; Nicotinic Agonists; Physician's Role; Primary Health Care; Propylamines; Treatment Outcome | 2006 |
Dissociable effects of noradrenaline, dopamine, and serotonin uptake blockade on stop task performance in rats.
Topics: Analysis of Variance; Animals; Atomoxetine Hydrochloride; Behavior, Animal; Citalopram; Conditioning, Operant; Dopamine; Dose-Response Relationship, Drug; Guanfacine; Inhibition, Psychological; Male; Neurotransmitter Uptake Inhibitors; Norepinephrine; Piperazines; Propylamines; Rats; Reaction Time; Selective Serotonin Reuptake Inhibitors; Serotonin; Task Performance and Analysis; Time Factors | 2009 |
Newly approved once-daily formulations of medications for the treatment of Attention Deficit (Hyperactivity) Disorder (ADHD) in children and adolescents.
Topics: Administration, Cutaneous; Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Delayed-Action Preparations; Dextroamphetamine; Drug Administration Schedule; Guanfacine; Humans; Lisdexamfetamine Dimesylate; Locus Coeruleus; Methylphenidate; Neurons; Nutrition Surveys; Prefrontal Cortex; Propylamines | 2010 |
Modulation of high impulsivity and attentional performance in rats by selective direct and indirect dopaminergic and noradrenergic receptor agonists.
Topics: Adrenergic Agonists; Animals; Animals, Outbred Strains; Atomoxetine Hydrochloride; Attention; Benzimidazoles; Choice Behavior; Dopamine Agonists; Guanfacine; Impulsive Behavior; Male; Methylphenidate; Piperazines; Propylamines; Quinpirole; Rats; Reaction Time; Serial Learning | 2012 |
Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorde
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Disorder with Hyperactivity; Child; Comparative Effectiveness Research; Delayed-Action Preparations; Guanfacine; Humans; Outcome and Process Assessment, Health Care; Pharmacoepidemiology; Propylamines; Randomized Controlled Trials as Topic | 2012 |
Treatment patterns, adherence, and persistence in ADHD: a Canadian perspective.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Analysis of Variance; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Clonidine; Cross-Sectional Studies; Drug Prescriptions; Drug Utilization Review; Female; Guanfacine; Humans; Male; Patient Compliance; Propylamines; Quebec; Retrospective Studies | 2012 |
Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008.
Topics: Adolescent; Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bupropion; Central Nervous System Stimulants; Child; Clonidine; Dopamine Uptake Inhibitors; Drug Utilization; Guanfacine; Humans; Practice Patterns, Physicians'; Propylamines; United States; United States Food and Drug Administration | 2013 |
Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Comparative Effectiveness Research; Delayed-Action Preparations; Dose-Response Relationship, Drug; Guanfacine; Humans; Propylamines; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome | 2013 |
A cost-effectiveness analysis of off-label atypical antipsychotic treatment in children and adolescents with ADHD who have failed stimulant therapy.
Topics: Adolescent; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Clonidine; Cost-Benefit Analysis; Decision Support Techniques; Guanfacine; Health Care Costs; Humans; Monte Carlo Method; Quality-Adjusted Life Years; Treatment Failure | 2016 |
Evaluating Matching-Adjusted Indirect Comparisons in Practice: A Case Study of Patients with Attention-Deficit/Hyperactivity Disorder.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bias; Child; Comparative Effectiveness Research; Female; Guanfacine; Humans; Male; Treatment Outcome | 2017 |
Pharmacotherapy of Attention Deficit Hyperactivity Disorder Symptom Profile in ASD.
Topics: Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Clonidine; Comorbidity; Cross-Sectional Studies; Guanfacine; Humans; Methylphenidate; Randomized Controlled Trials as Topic; Risperidone; Social Adjustment; Treatment Outcome | 2017 |
Healthcare utilization and costs of children with attention deficit/hyperactivity disorder initiating atomoxetine versus extended-release guanfacine.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Cohort Studies; Delayed-Action Preparations; Female; Guanfacine; Health Care Costs; Humans; Male; Patient Acceptance of Health Care; Retrospective Studies | 2018 |
Systemic administration of guanfacine improves food-motivated impulsive choice behavior primarily via direct stimulation of postsynaptic α
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic alpha-2 Receptor Antagonists; Animals; Atomoxetine Hydrochloride; Choice Behavior; Dose-Response Relationship, Drug; Feeding Behavior; Food; Guanfacine; Impulsive Behavior; Male; Methylphenidate; Motivation; Neurons; Random Allocation; Rats, Wistar; Receptors, Adrenergic, alpha-2 | 2018 |
Treatment of Adult ADHD without Stimulants: Effectiveness in A Dually Diagnosed Correctional Population.
Topics: Adrenergic Agents; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Comorbidity; Diagnosis, Dual (Psychiatry); Female; Follow-Up Studies; Guanfacine; Humans; Male; Mental Disorders; Nortriptyline; Outcome Assessment, Health Care; Prisoners; Retrospective Studies; Severity of Illness Index; Substance-Related Disorders | 2019 |
The use of reaction time distributions to study attention in male rats: the effects of atomoxetine and guanfacine.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Attention; Dose-Response Relationship, Drug; Guanfacine; Male; Norepinephrine; Rats; Rats, Sprague-Dawley; Reaction Time | 2019 |
The 10-year trend in drug prescriptions for attention-deficit/hyperactivity disorder (ADHD) in Germany.
Topics: Adolescent; Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Dextroamphetamine; Drug Prescriptions; Female; Germany; Guanfacine; Humans; Male; Methylphenidate; Practice Patterns, Physicians'; Young Adult | 2021 |
Lister hooded rats as a novel animal model of attention-deficit/hyperactivity disorder.
Topics: Animals; Atomoxetine Hydrochloride; Attention; Attention Deficit Disorder with Hyperactivity; Disease Models, Animal; Gene Expression Regulation; Guanfacine; Impulsive Behavior; Male; Maze Learning; Prefrontal Cortex; Rats; Rats, Inbred SHR; Rats, Inbred Strains; Rats, Wistar; Social Interaction; Species Specificity | 2020 |
Commentary: Identifying individualized predictions of response in ADHD pharmacotherapy - a commentary on Rodrigues et al. (2020).
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Child; Guanfacine; Humans; Methylphenidate | 2021 |
Noradrenergic contributions to cue-driven risk-taking and impulsivity.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Neurons; Adrenergic Uptake Inhibitors; Animals; Atomoxetine Hydrochloride; Cues; Decision Making; Dose-Response Relationship, Drug; Female; Gambling; Guanfacine; Impulsive Behavior; Male; Norepinephrine; Rats; Rats, Long-Evans; Reaction Time; Risk-Taking | 2021 |
Current use of attention-deficit hyperactivity disorder (ADHD) medications and clinical characteristics of child and adolescent psychiatric outpatients prescribed multiple ADHD medications in Japan.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Child; Female; Guanfacine; Humans; Japan; Logistic Models; Male; Methylphenidate; Outpatients; Prospective Studies; Retrospective Studies | 2021 |
Effects of two kinds of noradrenergic ADHD medicines on sign-tracking and goal-tracking in male rats.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Goals; Guanfacine; Male; Norepinephrine; Rats; Rats, Sprague-Dawley | 2022 |
Psychostimulants Modafinil, Atomoxetine and Guanfacine Impair Bone Cell Differentiation and MSC Migration.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cell Differentiation; Central Nervous System Stimulants; Child; Guanfacine; Humans; Ligands; Methylphenidate; Modafinil; Nootropic Agents; Osteoprotegerin; Receptor Activator of Nuclear Factor-kappa B | 2022 |